TICKERNERD
Menu
NVSTNVSTHealthcare · Medical Instruments & Supplies

NVST Stock Forecast: Envista Holdings Corp. Price Predictions for 2026-2027

Last close, 9 Sept 2026
$26
−1.45% on the day

The 16 Wall Street analysts covering Envista Holdings Corp. hold a median 12-month price target of $32 — +19.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 99 of 100 as at 8 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$4.4B
Ticker Nerd rank
99 / 100
Median analyst target
$32
Analysts covering
16
Revenue$730.5M+7.1% y/y
Operating income$80.3M
Net income$53.7M
Free cash flow$104.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.8%
1M
−6.1%
YTD
+21.7%
1Y
+27.0%
From 52W high
−12.7%
From 52W low
+39.4%
$19
$30
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

NVST stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Envista Holdings Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Sept 2026
99 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
96
Value
96
Issuance
85
Volatility
83
Momentum
77
Growth
73
Accruals
71
Quality
70
Size
25

Revisions (96): Analysts have, on balance, been raising their forecasts.

Quality (70): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Size (25): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

NVST stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NVST, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$25$30$35Oct 25Jan 26Apr 26Jul 26NVSTHigh $35Median $32Low $23

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says16 analysts
8 Buy8 Hold0 Sell
Low $23Median $32High $35

The green dot is the last close — the median target sits +19.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
3 Sept 2026JP MorganUpgradeOverweight$29 → $32
6 Aug 2026Piper SandlerReiteratesNeutral—
6 Aug 2026Piper SandlerReiteratesNeutral$26 → $28
29 July 2026Piper SandlerMaintainsNeutral$25 → $26
29 July 2026Piper SandlerMaintainsNeutral—
9 July 2026BMO CapitalInitiatesMarket Perform—
9 July 2026BMO CapitalInitiatesMarket Perform$27
11 June 2026BarclaysMaintainsOverweight—
7 May 2026BairdMaintainsOutperform—
7 May 2026Evercore ISI GroupMaintainsOutperform—
7 May 2026JP MorganMaintainsNeutral—
24 Apr 2026Morgan StanleyMaintainsEqual-Weight—
15 Apr 2026CitigroupInitiatesNeutral—
8 Apr 2026Evercore ISI GroupMaintainsOutperform—
11 Feb 2026BarclaysMaintainsOverweight—
10 Feb 2026MizuhoMaintainsNeutral—
6 Feb 2026JP MorganMaintainsNeutral—
6 Feb 2026Piper SandlerReiteratesNeutral—
6 Feb 2026StifelMaintainsBuy—
6 Feb 2026Wells FargoMaintainsEqual-Weight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NVST appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

NVST vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 9 Sept 2026, Envista Holdings Corp. returned +27.0% against +18.5% for the S&P 500, dividends included.

NVST vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130140Oct 25Jan 26Apr 26Jul 26NVSTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

NVST analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+7.3%
Analysts raising
16
Analysts cutting
0
Fundamentals

Envista Holdings Corp. (NVST) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
46.0×

Cheaper than 16% of US stocks

Price / sales
1.5×

Cheaper than 60% of US stocks

Price / book
1.4×

Cheaper than 60% of US stocks

EV / EBITDA
11.9×

Cheaper than 32% of US stocks

Growth & margins
Revenue growth (YoY)
7.1%

Higher than 44% of US stocks

Earnings growth (YoY)
103.4%

Higher than 84% of US stocks

Gross margin
55.7%

Higher than 69% of US stocks

Operating margin
10.4%

Higher than 65% of US stocks

Net margin
3.3%

Higher than 56% of US stocks

Returns & dividend
Return on equity
3.1%

Higher than 50% of US stocks

Return on assets
3.2%

Higher than 66% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Envista Holdings Corp. (NVST) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Envista Holdings Corp. has a market value of $4.4B and an enterprise value of $4.8B.

  • Revenue in the twelve months to 30 June 2026: $2.9B. The latest quarter grew 7.1% year on year.

  • Net income over the same four quarters: $95.0M, a 3.3% net margin.

  • Diluted earnings per share, trailing twelve months: $0.58.

  • Free cash flow in the twelve months to 30 June 2026: $248.1M.

  • Envista Holdings Corp. spent $169.3M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 160.6M.

  • Trailing P/E: 46.0×; forward P/E: 16.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Envista Holdings Corp. employs 12,000 people — $238K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Sept 2026

Data provided by Twelve Data

Peers

NVST vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
NVSTEnvista Holdings Corp.$4.4B
99
ICUIICU Medical, Inc.$4.0B
96
MMSIMerit Medical Systems, Inc.$5.2B
92
STVNStevanato Group SpA$5.5B
64
PLSEPulse Biosciences, Inc.$3.3B
42
TFXTeleflex, Inc.$6.1B
81
BLCOBausch + Lomb Corp.$6.3B
87

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Envista Holdings Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NVST news & analysis

NVST or ABT: Which Is the Better Value Stock Right Now?

Zacks Investment Research · 9 Sept 2026neutral

Zacks Investment Research published a comparison of Envista (NVST) and Abbott (ABT) as potential value stock picks in the Medical - Products sector. The article examines which of the two companies may be the better option for investors seeking undervalued stocks.

Why it matters — This comparison places NVST under analyst scrutiny as a potential value opportunity alongside a major peer, which is relevant for investors tracking the stock's valuation metrics.

Envista Announces Participation in Baird 2026 Global Healthcare Conference

PRNewsWire · 8 Sept 2026neutral

Envista Holdings Corporation announced it will participate in the Baird 2026 Global Healthcare Conference, as reported via PRNewswire from Brea, California.

Why it matters — Participation in a major healthcare conference gives NVST watchers an opportunity to hear company updates and engage with management in an industry setting.

Envista (NVST) Up 0.8% Since Last Earnings Report: Can It Continue?

Zacks Investment Research · 4 Sept 2026neutral

Envista (NVST) reported earnings 30 days ago, and its stock has risen 0.8% since that report. The article questions whether the stock can continue its recent upward momentum.

Why it matters — NVST watchers would care because the piece assesses the stock's performance since the latest earnings announcement and considers what may lie ahead.

4 PEG-Based Value Stocks to Buy as Investors Look Beyond AI

Zacks Investment Research · 28 Aug 2026positive

Zacks Investment Research highlights four value stocks, selected using PEG ratios, earnings growth and valuation metrics, for investors looking beyond AI. The article suggests these stocks stand out as potential winners based on these valuation criteria.

Why it matters — NVST watchers would care because the article points to value-based investing opportunities as investors rotate beyond AI-focused names, which could factor into how such stocks are evaluated.

Best Momentum Stocks to Buy for August 27th

Zacks Investment Research · 27 Aug 2026positive

EnVista Holdings Corp. (NVST) was included on Zacks Investment Research's Zacks Rank #1 (Strong Buy) momentum stocks list on August 27th, alongside ONTO and VIRT.

Why it matters — A NVST watcher would care because inclusion on Zacks' Strong Buy momentum list signals a positive ranking from a widely followed research service.

FAQ

Frequently asked questions about NVST stock

What is the NVST stock price forecast for 2026-2027?

The 16 Wall Street analysts covering Envista Holdings Corp. have a median 12-month price target of $32, with estimates ranging from $23 to $35. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NVST stock a buy right now?

Of the 16 analysts covering Envista Holdings Corp., 8 rate it a Buy, 8 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Envista Holdings Corp. 99 out of 100 across roughly 4,600 US stocks as at 8 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NVST?

As at 8 Sept 2026, Envista Holdings Corp. ranks 99 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (96 of 100).

Will NVST stock go up?

No one can know that. What the data says: the median 12-month target from 16 analysts implies +19.2% from the last close, and Ticker Nerd's factor model ranks Envista Holdings Corp. 99 out of 100 as at 8 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NVST stock forecast for 2030?

No analyst covering Envista Holdings Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NVST are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $23 to $35 over the next 12 months.

How has NVST stock performed over the past year?

Envista Holdings Corp. returned +27.0% over the 12 months to 9 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Envista Holdings Corp. do?

Envista Holdings Corp. is a global dental products company that develops, manufactures, and markets a broad range of solutions for dental professionals.

What is the latest news on NVST?

The most recent item we track (Zacks Investment Research, 9 Sept 2026): "NVST or ABT: Which Is the Better Value Stock Right Now?". Zacks Investment Research published a comparison of Envista (NVST) and Abbott (ABT) as potential value stock picks in the Medical - Products sector. The article examines which of the two companies may be the better option for investors seeking undervalued stocks.

Company

About Envista Holdings Corp.

Envista Holdings Corp. is a global dental products company that develops, manufactures, and markets a broad range of solutions for dental professionals. Its portfolio spans dental implants, orthodontic systems and aligners, imaging and digital workflow tools, restorative and endodontic products, and consumables used in everyday dental practice. The company serves clinical needs across prevention, diagnosis, treatment, and aesthetics, supporting dentists, oral surgeons, prosthodontists, and orthodontists with equipment, software, and branded consumables. Envista operates through two main business segments, Specialty Products & Technologies and Equipment & Consumables, and its products are used across dental offices, laboratories, and surgical settings worldwide. Headquartered in Brea, California, Envista holds a meaningful position in the dental technology and medical products market through a diversified family of dental brands.

CEO Mr. Paul A. Keel · 12,000 employees · United States · https://envistaco.com